The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksCalnex Solutio. Regulatory News (CLX)

Share Price Information for Calnex Solutio. (CLX)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 54.00
Bid: 53.00
Ask: 55.00
Change: 0.00 (0.00%)
Spread: 2.00 (3.774%)
Open: 54.00
High: 54.00
Low: 54.00
Prev. Close: 54.00
CLX Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Trading Update and Notice of Results

10 Oct 2023 15:17

RNS Number : 6739P
Calnex Solutions PLC
10 October 2023
 

This announcement contains inside information

 

10 October 2023

 

Calnex Solutions plc

("Calnex", the "Company" or the "Group")

 

Trading Update and Notice of Results

 

Calnex Solutions plc (AIM: CLX), a leading provider of test and measurement solutions for the global telecommunications and cloud computing markets, provides an update on trading and outlook for the full year to 31 March 2024 ("FY24") and beyond.

 

In the first six months of FY24, the Company's order inflow has remained at the subdued levels experienced at the start of the year, with the precise timing of future customer orders remaining uncertain. The cautiously improving outlook for the sector identified earlier this year has not developed momentum and the Company is aware that certain customers have elected to delay projects and associated orders in response to continuing wider economic uncertainty. These factors have led the Board to conclude that H2 FY24 will be slower than anticipated.

 

The challenging market conditions mean the Board now anticipates that, whilst revenues are expected to increase in H2 versus H1, revenues for FY24 will be in the region of 20-30 per cent below current market expectations, depending on the timing of orders. No customer orders have been cancelled and all are expected to be fulfilled once the delays to customer project spending are relaxed.

 

The Company's balance sheet remains robust, with cash at the end of September 2023 of £13.5 million, following investment in inventory. The cash position enables the Company to continue to target growth opportunities in its key sectors and maintain relationships with customers as they plan future investment in their projects.

 

Calnex's sales pipeline remains strong and the Company's close relationships with its customers leaves it well positioned to convert the sales pipeline to orders once spending patterns normalise.

 

The Board is confident in a return to growth in FY25, with Calnex able to deploy its suite of products to target opportunities in both the Telecoms and Cloud-computing and related sectors. Costs are closely monitored with investment in new products subject to stringent assessment.

 

The Company is actively targeting new markets with its expanded product range, and recently launched, or soon to be launched, enhanced product lines within existing and new key markets, include:

 

· Sentry timing product to address the large data centre market.

· SNE-Ignite and SNE-X products have been designed to prove the performance of new, real-time cloud-based applications.

· NE-ONE, Calnex's recently acquired network emulation product, is targeting defence and government markets.

· Enhancement to the Paragon platform, through a major new release in H2 FY25 to support leading edge 800Gb/s interface testing.

· SyncSense, Calnex's newly-developed data centre and telecom network management timing product, has been well received by customers.

 

These products will enhance penetration in the Company's target markets, reinforcing the potential for growth in FY25 and beyond.

 

Notice of Results

 

The Company intends to announce unaudited results for the six months ended 30 September 2023 on Tuesday 21 November 2023.

 

Tommy Cook, Chief Executive Officer, and founder of Calnex, said: "Whilst the telecommunications market outlook is currently challenging, the expansion of our product portfolio to areas outside of telecommunications and our strong sales pipeline mean we are confident in a return to growth in FY25.

 

"Looking to the longer-term, the underlying market drivers continue to build, such as the need to upgrade telecoms infrastructure to deliver the promise of 5G, and to enhance data centre operations to support the demand for cloud computing and advancements in AI and Virtual Reality technologies. As a result, our confidence in the long-term prospects for Calnex remains high."

 

 

For more information, please contact:

 

Calnex Solutions plc

Via Alma PR

Tommy Cook, Chief Executive Officer

Ashleigh Greenan, Chief Financial Officer

Cavendish Securities plc - NOMAD

+44 (0)131 220 6939

Derrick Lee, Peter Lynch

 

Alma

+ 44(0) 20 3405 0213

Caroline Forde, Hannah Campbell, Joe Pederzolli

 

 

Overview of Calnex

 

Calnex Solutions designs, produces and markets test and measurement instrumentation and solutions for the telecoms and cloud computing industries. Calnex's portfolio enables R&D, pre-deployment and in-service testing for network technologies and networked applications, enabling its customers to validate the performance of the critical infrastructure associated with telecoms and cloud computing networks and the applications that run on it.

 

To date, Calnex has secured and delivered orders in 68 countries across the world. Customers include BT, China Mobile, NTT, Ericsson, Nokia, Intel, Qualcomm, IBM and Meta.

 

Founded in 2006, Calnex is headquartered in Linlithgow, Scotland, with additional locations in Belfast, Northern Ireland, Stevenage, England and California in the US, supported by sales teams in China and India. Calnex has a global network of partners, providing a worldwide distribution capability. 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
TSTBSBDGUBBDGXG
Date   Source Headline
10th Apr 20247:00 amRNSNotice of Investor Presentation
3rd Apr 20247:00 amRNSFY24 Trading Update and Notice of Results
21st Feb 20249:28 amRNSExercise of Options
14th Feb 20241:08 pmRNSExercise of Options
12th Dec 20233:47 pmRNSPDMR Dealings
21st Nov 20237:00 amRNSInterim Results
1st Nov 202312:24 pmRNSChange of Nominated Adviser
26th Oct 20237:00 amRNSNotice of Investor Presentation
10th Oct 20233:17 pmRNSTrading Update and Notice of Results
25th Aug 20234:36 pmRNSPDMR Dealings
16th Aug 20231:22 pmRNSResult of AGM
16th Aug 20237:00 amRNSAGM Statement
11th Aug 20232:00 pmRNSLong-Term Incentive Plan Awards
17th Jul 20237:00 amRNSNotice of AGM
12th Jul 202312:05 pmRNSDirector/PDMR Dealings
12th Jun 20234:34 pmRNSPDMR Dealings
23rd May 20237:00 amRNSFY23 Final Results
11th May 20239:00 amRNSPDMR Dealings
4th May 20237:00 amRNSNotice of Results and Investor Presentation
14th Apr 20236:03 pmRNSPDMR Dealings
14th Apr 20233:24 pmRNSDirector Dealing
15th Mar 20231:15 pmRNSDirector Dealings
14th Mar 20234:00 pmRNSPDMR Dealings
7th Mar 20239:05 amRNSSecond Price Monitoring Extn
7th Mar 20239:00 amRNSPrice Monitoring Extension
7th Mar 20237:00 amRNSTrading Update
15th Feb 202310:59 amRNSPDMR Dealings
19th Jan 20239:56 amRNSPDMR Dealings
17th Jan 20239:56 amRNSDirector / PDMR Dealings
17th Jan 20239:52 amRNSHolding(s) in Company
17th Jan 20237:00 amRNSBoard Changes
13th Jan 20234:00 pmRNSDirector/PDMR Dealing
13th Dec 20222:15 pmRNSDirector / PDMR Dealings
22nd Nov 20227:00 amRNSInterim Results
21st Nov 20225:43 pmRNSDirector / PDMR Dealings
27th Oct 20227:00 amRNSNotice of Results and Investor Presentation
14th Oct 20223:53 pmRNSDirector/PDMR Shareholding
12th Oct 20221:29 pmRNSDirector / PDMR Dealings
15th Sep 20227:30 amRNSDirector/PDMR Dealing
17th Aug 20225:26 pmRNSResult of AGM
17th Aug 20227:00 amRNSAGM Statement
15th Aug 202210:26 amRNSDirector / PDMR Dealings
26th Jul 20223:33 pmRNSDirector / PDMR Shareholding
18th Jul 20227:00 amRNSNotice of AGM
14th Jul 20225:49 pmRNSDirector/PDMR Dealings
8th Jul 20226:01 pmRNSDirector / PDMR dealings
15th Jun 20227:00 amRNSExercise of Options
14th Jun 20227:00 amRNSBoard Update
6th Jun 20221:30 pmRNSDirector Dealing
24th May 20227:00 amRNSFY22 Final Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.